SIGA TechnologiesSIGA
SIGA
About: SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Employees: 45
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
95% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 19
94% more call options, than puts
Call options by funds: $7.74M | Put options by funds: $3.99M
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
12% more funds holding
Funds holding: 151 [Q2] → 169 (+18) [Q3]
1.94% more ownership
Funds ownership: 48.01% [Q2] → 49.95% (+1.94%) [Q3]
7% less capital invested
Capital invested by funds: $259M [Q2] → $241M (-$18.7M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for SIGA.
Financial journalist opinion
Based on 6 articles about SIGA published over the past 30 days
Positive
Zacks Investment Research
17 hours ago
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
2 weeks ago
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?
Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
2 weeks ago
Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients. Data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints.
Positive
Zacks Investment Research
2 weeks ago
Should Value Investors Buy Siga Technologies (SIGA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
2 weeks ago
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Negative
Seeking Alpha
3 weeks ago
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox.
Neutral
Seeking Alpha
1 month ago
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
SIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. The mpox outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat.
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
GlobeNewsWire
1 month ago
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.
Neutral
Seeking Alpha
1 month ago
SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon, ladies and gentlemen, and welcome to the SIGA Technologies Third Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode.
Charts implemented using Lightweight Charts™